Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Treatment of opioid dependence (FDA-approved),Maintenance therapy for opioid use disorder,Off-label: chronic pain management (limited use)
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine; naloxone is metabolized by UDP-glucuronosyltransferases (UGT1A1, UGT1A3).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Buprenorphine: ~96% bound to alpha- and beta-globulins; naloxone: ~45% bound to albumin (primarily).
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Buprenorphine: Vd ~2.5-4.0 L/kg (large distribution due to lipophilicity); naloxone: Vd ~2.0 L/kg.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Sublingual buprenorphine: ~30-50% (avoid first-pass); sublingual naloxone: ~10% (low); IV: 100% both.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
For GFR <30 m L/min: use with caution, dose reduction may be necessary; avoid in severe impairment (creatinine clearance <15 m L/min) due to naloxone accumulation.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50%, monitor for oversedation. Child-Pugh Class C: not recommended.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Not approved for pediatric patients under 16 years for opioid use disorder; safety and efficacy not established.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Initiate at lower end of dosing range (e.g., 2/0.5 mg sublingually once daily) due to increased sensitivity and potential for hepatic/renal impairment; titrate slowly and monitor for CNS depression.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Risk of respiratory depression, particularly in patients using other CNS depressants, and risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Respiratory depression risk with intravenous administration,Hepatotoxicity (elevated liver enzymes, hepatic failure),Adrenal insufficiency with chronic use,Interaction with benzodiazepines and other CNS depressants,Precipitation of withdrawal in opioid-dependent patients if administered too soon after last opioid use,Dependence and abuse potential (Schedule III controlled substance),Neonatal opioid withdrawal syndrome if used during pregnancy
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Hypersensitivity to buprenorphine or naloxone,Severe respiratory insufficiency (e.g., acute asthma, COPD),Severe hepatic impairment,Patients with acute intoxication (alcohol, opioids, benzodiazepines),Concurrent use of MAO inhibitors (relative contraindication)
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
No significant food interactions; grapefruit juice may increase buprenorphine levels but not considered clinically relevant; alcohol is contraindicated due to additive CNS depression; take on an empty stomach or with food if GI upset occurs.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use. No known specific teratogenicity; however, maternal opioid use may lead to fetal growth restriction, preterm birth, and stillbirth. Buprenorphine/naloxone is preferred over methadone in pregnancy due to less neonatal respiratory depression and NOWS severity.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Limited data; buprenorphine and naloxone are excreted into breast milk in low concentrations. The M/P ratio for buprenorphine is approximately 0.5–2.5, with high interindividual variability. Naloxone has poor oral bioavailability, reducing infant exposure. Benefits of breastfeeding likely outweigh risks if mother is stable on treatment. Monitor infant for sedation, respiratory depression, and adequate weight gain. Avoid use during breastfeeding in cases of high maternal doses or concurrent substance abuse.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Pregnancy may require dose increases due to increased plasma volume, enhanced clearance, and changes in protein binding. Buprenorphine is extensively metabolized by CYP3A4, which may be induced during pregnancy. Aim to maintain trough levels to prevent withdrawal. Usually, doses are adjusted based on clinical response (withdrawal symptoms, cravings). No fixed dose adjustment; individual titration is necessary. Higher doses (up to 50% increase) may be needed in late pregnancy. Postpartum, doses should be tapered back to prepregnancy levels gradually.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Avoid in patients with known respiratory insufficiency or acute opioid intoxication; use with caution in hepatic impairment; buprenorphine has a ceiling effect for respiratory depression; naloxone component prevents IV abuse; monitor for precipitated withdrawal if initiated too soon after last opioid use; requires at least 12 hours since last short-acting opioid or 24-72 hours for long-acting opioids; can cause QT prolongation at high doses; sublingual absorption is critical; consider dose adjustment in renal impairment.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
Place the tablet/film under the tongue until fully dissolved; do not chew, swallow, or crush.,Do not use alcohol or other sedatives (benzodiazepines, muscle relaxants, sleeping pills) as this can cause severe respiratory depression or coma.,Keep out of reach of children and pets; accidental ingestion is life-threatening.,Avoid driving or operating machinery until you know how the medication affects you.,Do not stop suddenly; withdrawal symptoms can occur; taper under medical supervision.,Store at room temperature away from moisture and heat.,Tell all healthcare providers you are taking this medication before any surgery or new prescriptions.,Seek emergency help if you experience difficulty breathing, chest pain, or signs of allergic reaction (rash, swelling).,If you miss a dose, skip it; do not double dose.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is: Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ALFENTANIL and BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.